Abstract
Hepatitis C virus (HCV) is a more important factor associated with hepatocellular carcinoma than hepatitis B virus (HBV) in Japan and certain Western countries [1–3]. Some patients who contracted chronic non-A, non-B hepatitis after blood transfusion and hepatocellular carcinoma many years later have been studied in detail [4–6]. These studies proved that patients with chronic HCV infection often develop hepatocellular carcinoma [7]. The cumulative incidence of hepatocellular carcinoma in patients who had blood transfusions and were negative for hepatitis B surface antigen (HBsAg) was 53% (13/26) during 6 years of observation [8]. All of these patients had HCV antibodies. The mechanism by which hepatocellular carcinoma develops in the presence of HCV is unknown.
Supported in part by a grant from the Ministry of Welfare, Japan
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bruix J, Barrera JM, Calvet X, et al (1989) Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet ii:1004–1006
Colombo M, Kuo G, Choo QL, et al (1989) Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet ii: 1006–1008
Nishioka K, Watanabe J, Furuta S, et al (1991) A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 67:429–433
Resnick RH, Stone K, Antonioli D (1983) Primary hepatocellular carcinoma following non-A, non-B posttransfusion hepatitis. Dig Dis Sci 28:908–911
Kiyosawa K, Akahane Y, Nagata A, Furuta S (1984) Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis. Am J Gastroenterol 79:777–781
Gilliam JH II, Geisinger KR, Richter JE (1984) Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis. Ann Intern Med 101:794–795
Tremolada F, Benvegnu L, Casarin C, Pontisso P, Tagger A Alberti A (1990) Antibody to hepatitis C virus in hepatocellular carcinoma. Lancet 335:300–301
Oka H, Kurioka N, Kim K, et al (1990) Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 12:680–687
Hoofnagle JH, Mullen KD, Jones DB, et al (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 315:1575–1578
Di Bisceglie AM, Martin P, Kassianides C, et al (1989) Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind placebo-controlled trial. N Engl J Med 321:1506–1510
Shindo M, Di Bisceglie AM, Hoofnagle JH (1992) Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology 15:1013–1016
Kiyosawa K, Sodeyama T, Tanaka E, et al (1990) Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12:671–675
Knodell RG, Ishak KG, Black WC, et al (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435
Pugh RNH, Murray-Lyon IM, Dawson JL, et al (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649
Sherlock S, Dooley J (1997) Diseases of the liver and biliary system, 9th edn. Blackwell, Oxford, p 367
Hill AB (1963) Medical ethics and controlled trials. Br Med J i:1043–1049
Nishiguchi S, Kuroki T, Ueda T, et al (1992) Detection of hepatitis C virus antibody in the absence of viral RNA in patients with autoimmune hepatitis. Ann Intern Med 116:21–25
Okamoto H, Tokita H, Sakamoto M, et al (1993) Characterization of the genomic sequence of type V (or 3a) hepatic C virus isolates and PCR primers for specific detection. J Gen Virol 74:2835–2890
Nishiguchi S, Kuroki T, Nakatani S, et al (1995) Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051–1056
Mazzella G, Accogli E, Sottili S, et al (1996) Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24:141–147
Fattovich G, Giustina G, Degos F, et al (1997) Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 27:201–205
Chisari FV, Klopchin K, Moriyama T, et al (1989) Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59:1145–1156
Vogelstein B, Fearon ER, Hamilton SR, et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532
Okuda K (1992) Hepatocellular carcinoma: recent progress. Hepatology 15:948–963
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Tokyo
About this paper
Cite this paper
Nishiguchi, S. et al. (1999). Use of Interferon-α for Prevention of Hepatocellular Carcinoma in Patients with Chronic Active Hepatitis C with Cirrhosis. In: Okita, K. (eds) HCV and Related Liver Diseases. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68488-6_8
Download citation
DOI: https://doi.org/10.1007/978-4-431-68488-6_8
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-68490-9
Online ISBN: 978-4-431-68488-6
eBook Packages: Springer Book Archive